Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00178620 · ClinicalTrials.gov registry record · Phase 4

Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization

A Phase 4 study of Myocardial Infarction and Heart Disease, sponsored by The University of Texas Health Science Center, Houston.

Completed
Registry status
Phase 4
Development phase
390
Enrollment target
1
Study location

NCT00178620: Completed Phase 4 study of Myocardial Infarction and Heart Disease, sponsored by The University of Texas Health Science Center, Houston.

NCT00178620 is a Phase 4 study of Myocardial Infarction and Heart Disease that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 390 participants, below the 4,676-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00178620, a Phase 4 study of Myocardial Infarction and Heart Disease, has completed, sponsored by The University of Texas Health Science Center, Houston.

COMPLETED
Registry status
Phase 4
Development phase
390 participants
Enrollment target
1
Study location

Study Summary

The PATCAR study has been designed to test the hypothesis that the strategy of pre-hospital use of a "clot busting" (thrombolytic) drug followed with emergent heart catheterization including stenting of the problematic coronary artery, will result in a lower mortality and reduced repeat heart attack rates. Early identifying and treating heart attacks patients prior to the arriving at the hospital, in those patients who qualify for the "clot busting" drugs will lower the size of the heart attack damage. This smaller heart attack will lead to fewer problems with less repeat heart attacks and death in the future.

Interventions

  • DRUG Reteplase 10 Units (U) plus a second dose of reteplase 10 U
  • DRUG Reteplase 10 U
  • PROCEDURE Urgent Percutaneous Coronary Intervention (PCI)
  • PROCEDURE Primary Percutaneous Coronary Intervention (PCI)

Study Locations (1)

Texas

  • Memorial Hermann Hospital / The University of Texas HSC - Houston

Trial Details

FieldValue
Enrollment Target 390 participants
Start Date 2003-09
Est. Completion 2009-12
Phase Phase 4

What the finished NCT00178620 record still lists

NCT00178620 is an interventional study that assigns participants to a tested intervention. The registered 390 participants enrollment target is mid-sized for trials with a published cap, below the 4,676-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (92% lower).

The record links to 3 conditions, with Myocardial Infarction appearing as the primary indexed condition, and to 4 interventions - of which Reteplase 10 Units (U) plus a second dose of reteplase 10 U is the first listed.

NCT00178620 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT00178620 about?

NCT00178620 is a clinical study titled "Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization". The PATCAR study has been designed to test the hypothesis that the strategy of pre-hospital use of a "clot busting" (thrombolytic) drug followed with emergent heart catheterization including stenting of the problematic coronary artery, will result in a lower mortality and reduced repeat heart attack...

What is the current status of trial NCT00178620?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 390 participants. The study started on 2003-09. Estimated completion is 2009-12.

What conditions does trial NCT00178620 study?

This clinical trial studies the following conditions: Myocardial Infarction, Heart Disease, Acute Myocardial Infarction.

What interventions are being tested in trial NCT00178620?

The interventions under investigation include: Reteplase 10 Units (U) plus a second dose of reteplase 10 U (DRUG), Reteplase 10 U (DRUG), Urgent Percutaneous Coronary Intervention (PCI) (PROCEDURE), Primary Percutaneous Coronary Intervention (PCI) (PROCEDURE).

Who is sponsoring clinical trial NCT00178620?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00178620 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myocardial Infarction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00178620's enrollment target sits among peer trials

390 31st of 64 higher than 34 of 64 other Myocardial Infarction trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Myocardial Infarction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00397111 · 390 participants

    Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders

  • NCT05335928 · 390 participants · Phase 3

    Abatacept in Immune Checkpoint Inhibitor Myocarditis

  • NCT05445960 · 390 participants · NA

    Correlation Between Intraoperative Tourniquet Use and Limb pH, Functional Measures and Patient-reported Outcomes After Ankle Fracture Surgery

  • NCT05997615 · 390 participants · Phase 1

    Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00178620, the US trial registry maintained by the National Library of Medicine. NCT00178620 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.